In This Article:
RADNOR, PA / ACCESSWIRE / December 30, 2021 / The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that a securities class action lawsuit has been filed against Ginkgo Bioworks Holdings, Inc. ("Ginkgo") (NYSE:DNA) f/k/a Soaring Eagle Acquisition Corp.(NASDAQ:SRNG). The action charges Ginkgo with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company's business, operations, and prospects. As a result of Ginkgo's materially misleading statements to the public, Ginkgo investors have suffered significant losses.
CANNOT VIEW THIS VIDEO? PLEASE CLICK HERE
CLICK HERE TO SUBMIT YOUR GINKGO LOSSES
LEAD PLAINTIFF DEADLINE: January 18, 2022
CLASS PERIOD: May 11, 2021 through October 5, 2021
CONTACT AN ATTORNEY TO DISCUSS YOUR RIGHTS:
James Maro, Esq. (484) 270-1453 or Toll Free (844) 887-9500 or Email at info@ktmc.com
GINKGO'SALLEGED MISCONDUCT
Ginkgo, headquartered in Boston, is a biotech company that develops platforms for cell programming which are used to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals currently derived from petroleum.
On October 6, 2021, analyst Scorpion Capital published an investigative report concluding "Ginkgo is a house of cards - in our opinion, one of the most brazen frauds of the last 20 years." The report indicated that Ginkgo's business model is a related-party model whereby essentially 100% of the company's deferred revenue are derived from related-party "customers" it created, funded, controls or influences via its ownership position and board seats. Scorpion also alleged that Ginkgo has engaged in a brazen effort to misclassify and misreport related-party revenue and deceive investors with phony accounting and at least half of Ginkgo's reported foundry revenue is phantom, non-cash and "pure accounting hocus-pocus."
Following this news, Ginkgo's stock price fell $1.39, or approximately 12%, to close at $10.59 per share on October 6, 2021.
Recently, on November 15, 2021, Ginkgo admitted that shortly after the issuance of the Scorpion Capital report, the company received an inquiry from the United States Department of Justice relating to the financial misconduct allegations in the report.
WHAT CAN I DO?
Ginkgo investors may, no later than January 18, 2022, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. Kessler Topaz Meltzer & Check, LLPencourages Ginkgo investors who have suffered significant losses to contact the firm directly to acquire more information.